Researchers discuss the potential of enobosarm, a selective androgen receptor modulator, for the treatment of ER-positive breast cancer that has progressed on at least 1 previous endocrine therapy.
FDA-approved oral and injectable treatment options for breast cancer.
The number of genes tested for ovarian and breast cancer has grown, but most patients do not undergo testing, and variant-of-unknown-significance results are common, especially among minority populations.
Researchers identified the genes that may allow for a better prediction of risk for breast cancer.
Investigators measured responses to endocrine therapy by monitoring the change in tumor uptake of the progestin analog 21-[18F] fluorofuranylnorprogesterone (FFNP) before and after a 1-day estradiol challenge.
Researchers sought to determine the effects of dual therapy of aromatase inhibitor or tamoxifen with GnRHa in men with breast cancer.
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
The phase 3 SOPHIA trial tested the safety and efficacy of margetuximab plus chemotherapy vs trastuzumab with chemotherapy in patients with ERRB2-positive advanced breast cancer.
The retrospective population-based study examined opioid and benzodiazepine use in patients with breast cancer receiving curative-intent therapy for their disease.
The CARG-BC risk score was developed to accurately and specifically stratify risk of chemotherapy toxicity in patients 65 and older with early-stage breast cancer.
